Bricitan is a novel synaptic vesicle protein 2A (SV2A) highly selective ligand, belonging to the pyrrolidinone derivative, used as an adjuvant therapy for controlling focal seizures in epilepsy.

1、 Drug name:

1. Product Name: BRIVIACT

2. Common name: brivaracetam

2、 Indications:

Used to treat partial seizures of epilepsy in patients aged 1 month or more.

3、 Specifications:

Tablets: 100mg.

4、 Main components:

Active ingredient: brivaracetam

5、 Usage and dosage:

1. Adults (16 years old and above): The recommended starting dose is 50mg twice daily for monotherapy or adjuvant therapy (total daily dose 100mg). According to individual patient tolerance and treatment response, the dosage can be adjusted to 25mg twice daily (total daily dose 50mg) or 100mg twice daily (total daily dose 200mg).

2. Pediatric patients (1 month to under 16 years old): The recommended dosage is based on body weight and taken orally twice a day.

6、 Dose adjustment:

1. Liver injury patients: It is recommended to adjust the dosage for all stages of liver injury.

2. When used in combination with rifampicin: it is recommended to increase the dose of budesonide to twice its original amount.

7、 Medication precautions:

1. Before and after meals: Bu Li Xi Tan can be taken with food or on an empty stomach.

2. Missed dose: If missed once, it should be taken as soon as possible when remembered, unless it is close to the next dose. If the next dose is approaching, skip the missed dose and take the next dose at the regular time.

3. Vomiting: If vomiting occurs after taking medication, do not take another dose and take the next dose at the usual time.

8、 Medication for special populations:

1. Pregnant women: Based on animal data, it may cause harm to the fetus.

2. Breastfeeding women: Burixitan can be secreted into human milk, but its effects on infants are not yet clear.

3. Pediatric patients: The safety and efficacy of patients aged 1 month to 16 years have been established, while the safety and efficacy of patients under 1 month have not yet been established.

4. Elderly patients: Data on patients aged 65 and above is limited, and medication should be taken with caution, usually starting from the lower values of the dosage range.

9、 Adverse reactions:

1. Common adverse reactions (in adults): drowsiness/sedation, dizziness, fatigue, nausea/vomiting.

2. Pediatric patients: Common adverse reactions are similar to those in adults.

3. Serious adverse reactions: including suicidal behavior and ideation, neurological adverse reactions, psychiatric adverse reactions, allergic reactions (bronchospasm and angioedema), severe skin reactions, and withdrawal from antiepileptic drugs.

10、 Contraindications:

It is contraindicated for individuals allergic to any non active ingredients in budesonide or BRIVIACT.

11、 Drug interactions:

1. When used in combination with rifampicin, the plasma concentration of bupivacaine may decrease, and it is recommended to increase the dosage.

2. When used in combination with carbamazepine, the exposure of carbamazepine metabolites may increase. If tolerance issues arise, reducing the dose of carbamazepine should be considered.

3. When used in combination with phenytoin, the plasma concentration of phenytoin may increase, and phenytoin levels should be monitored.

4. When used in combination with levetiracetam, there is no additional therapeutic benefit of budesonide.

12、 Storage method:

Stored at 25 ° C (77 ° F), with a permissible temperature fluctuation range of 15 ° C to 30 ° C (59 ° F to 86 ° F).

Briviactinformation